Hypothesis versus association: The optimal hemoglobin target debate

Giovanni F.M. Strippoli; Jonathan C. Craig

doi:10.1053/j.ajkd.2005.09.009

Hypothesis versus association: The optimal hemoglobin target debate

Giovanni F.M. Strippoli, Jonathan C. Craig

Research output: Contribution to journal › Editorial

9 Citations (Scopus)

Abstract

IN THIS ISSUE of the American Journal of Kidney Diseases, Levin et al1 present the results of their Canadian randomized trial of early versus delayed anemia management with high (12.0 to 14.0 g/dL [120 to 140 g/L]) versus low (9.0 to 10.5 g/dL [90 to 105 g/L]) hemoglobin (Hb) level targets in patients with chronic kidney disease (CKD). This study is presented within a year of the publication of 2 other trials with similar designs addressing similar questions2, 3 and when preliminary results of the Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study are coming into the public domain.4

Original language	English
Pages (from-to)	970-973
Number of pages	4
Journal	American Journal of Kidney Diseases
Volume	46
Issue number	5
DOIs	https://doi.org/10.1053/j.ajkd.2005.09.009
Publication status	Published - 2005
Externally published	Yes

Keywords

CREATE stutdy
anemia management
bias
randomization
outcomes

Access to Document

10.1053/j.ajkd.2005.09.009Licence: In Copyright

Cite this

@article{6c98754a64b14fa2995ef86092216b74,

title = "Hypothesis versus association: The optimal hemoglobin target debate",

abstract = "IN THIS ISSUE of the American Journal of Kidney Diseases, Levin et al1 present the results of their Canadian randomized trial of early versus delayed anemia management with high (12.0 to 14.0 g/dL [120 to 140 g/L]) versus low (9.0 to 10.5 g/dL [90 to 105 g/L]) hemoglobin (Hb) level targets in patients with chronic kidney disease (CKD). This study is presented within a year of the publication of 2 other trials with similar designs addressing similar questions2, 3 and when preliminary results of the Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study are coming into the public domain.4",

keywords = "CREATE stutdy, anemia management, bias, randomization, outcomes",

author = "Strippoli, {Giovanni F.M.} and Craig, {Jonathan C.}",

year = "2005",

doi = "10.1053/j.ajkd.2005.09.009",

language = "English",

volume = "46",

pages = "970--973",

journal = "American Journal of Kidney Diseases",

issn = "0272-6386",

publisher = "American Journal of Kidney Diseases",

number = "5",

}

TY - JOUR

T1 - Hypothesis versus association

T2 - The optimal hemoglobin target debate

AU - Strippoli, Giovanni F.M.

AU - Craig, Jonathan C.

PY - 2005

Y1 - 2005

N2 - IN THIS ISSUE of the American Journal of Kidney Diseases, Levin et al1 present the results of their Canadian randomized trial of early versus delayed anemia management with high (12.0 to 14.0 g/dL [120 to 140 g/L]) versus low (9.0 to 10.5 g/dL [90 to 105 g/L]) hemoglobin (Hb) level targets in patients with chronic kidney disease (CKD). This study is presented within a year of the publication of 2 other trials with similar designs addressing similar questions2, 3 and when preliminary results of the Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study are coming into the public domain.4

AB - IN THIS ISSUE of the American Journal of Kidney Diseases, Levin et al1 present the results of their Canadian randomized trial of early versus delayed anemia management with high (12.0 to 14.0 g/dL [120 to 140 g/L]) versus low (9.0 to 10.5 g/dL [90 to 105 g/L]) hemoglobin (Hb) level targets in patients with chronic kidney disease (CKD). This study is presented within a year of the publication of 2 other trials with similar designs addressing similar questions2, 3 and when preliminary results of the Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study are coming into the public domain.4

KW - CREATE stutdy

KW - anemia management

KW - bias

KW - randomization

KW - outcomes

U2 - 10.1053/j.ajkd.2005.09.009

DO - 10.1053/j.ajkd.2005.09.009

M3 - Editorial

SN - 0272-6386

VL - 46

SP - 970

EP - 973

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

IS - 5

ER -

Hypothesis versus association: The optimal hemoglobin target debate

Abstract

Keywords

Access to Document

Fingerprint

Cite this